Navigation Links
Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Date:6/1/2009

e NDA submission will not be completed in the second quarter of 2009, that priority review will not be granted by the FDA and that a decision by the FDA is not rendered in late 2009, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors

    Medical Information Contact:
    T: 800.715.0944
    E: info@askarm.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
3. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
4. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
5. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
6. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
7. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
8. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
9. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
10. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
11. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... - On Aug. 20, at its annual meeting in ... (CMA) voted on and approved a delegate resolution opposing ... Bedrocan Cannabis Corp., a leading Canadian licensed producer of ... The CMA is quite right to point out ... plant material, including medicinal cannabis. While some patients, particularly ...
(Date:8/22/2014)... Research and Markets  has announced the addition of ... Technologies" report to their offering. ... you wish to expand your product line, you,ll know ... authors know you want to make effective product development ... improved revenues and take market share from your competition. ...
(Date:8/22/2014)... 22, 2014  Dr. Mark Rasak , MD ... Lifetime Achievement Award in the field of Medicine as ... Clinical Associates. Dr. Rasak has over 15 ... aspects of the business; overseeing the daily operations; interventional ... intervention. In addition, he is an honored Fellow of ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... 2011 EMKinetics, Inc. announced today initiation of ... trial for patients suffering from urge incontinence and ... at 10-15 US centers.  Submission for CE mark ... the study.   EMKinetics, TranStim therapy builds on ...
... 2011 Masimo (NASDAQ: MASI ) announced ... period ended October 1, 2011, after the market closes on October ... at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted ... de Raad, Executive Vice President and Chief Financial Officer. ...
Cached Medicine Technology:EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 2Masimo to Report Third Quarter 2011 Financial Results After Market Close on October 25, 2011 3
(Date:8/22/2014)... Many Americans know little about how Ebola is transmitted and ... the United States, a new survey shows. About four ... be a major Ebola outbreak in the United States, and ... will get sick with the deadly virus in the next ... poll. However, those opinions don,t match reality, the Harvard ...
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
(Date:8/22/2014)... Millennium Treatment Group, a drug ... recently launched a new website. Patients, parents, loved ... now find Millennium Treatment Group at http://www.millenniumtreatmentgroup.com ... at the beginning of July. Everything anyone would ... found on the website. There’s an About Us ...
(Date:8/22/2014)... 22, 2014 Natural Clear Vision , ... restore his own vision from legally blind to perfect 20/20 ... investigative review. , “There is a huge portion of ... everyday function, and most people just think that’s the way ... surgery that can be pretty risky at times,” reports Michaels. ...
(Date:8/22/2014)... Beat Eczema , Susan Clark’s ... natural methods to completely cure the eczema symptoms they ... Shane Michaels, prompting an investigative review. , “Although ... it can still be extremely debilitating and life-altering for ... itching and pain that it causes on the skin ...
Breaking Medicine News(10 mins):Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Millennium Treatment Group Has a New Website 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2
... 1 Misonix, Inc., (Nasdaq: MSON ), a ... Europe is used for the ablation of tumors and worldwide ... of its direct sales channel for the United States, which ... already established, commission based, contract sales organization, the Company has ...
... , KNOXVILLE, Tenn., Sept. ... Joint Commission,s intra-cycle certification, a program that offers an ... provide competent staffing services. This certification follows Spectrum,s third ... in 2008. , , "Healthcare organizations ...
... , , , ... sixth season of the Thrive advertising campaign, with television, radio, print ... the total health of its members and the communities it serves. ... and "Connected" -- illustrate Kaiser Permanente,s leadership in leveraging health information ...
... , PORTLAND, Ore., Sept. 1 ... Award recognizing the Administrator software for its innovative contributions to Senior ... Awards Program is the first awards program of its kind to ... families and care providers. Entries were judged by a distinguished panel ...
... , , HOUSTON, Sept. 1 ... is the first hospital in Houston to feature the CyberKnife((R)), a ... tumors. , , The CyberKnife((R)) is the world,s ... of high-dose radiation with extreme accuracy throughout the body, including the brain, ...
... Medicaid Savings Could Surpass $59 Billion , , ... to reach an additional 20 million patients as part of national health ... the ten-year period 2010 to 2019, including federal Medicaid savings of $59 ... of the health center investment of $38.8 billion called for in the ...
Cached Medicine News:Health News:Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States 2Health News:Misonix Expands Sales Organization for Direct Sales of the SonicOne(TM) Wound Management System and the SonaStar(R) Ultrasonic Surgical Aspirator in the United States 3Health News:Joint Commission Recognizes Spectrum Healthcare Resources 2Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 2Health News:Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 3Health News:Vigilan Earns Honor in the 2009 Product & Technology Awards Program by Mature Market Resource Center 2Health News:St. Luke's Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 2Health News:St. Luke's Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 3Health News:Increasing Health Center Capacity by 20 Million Patients Could Save More Than $200 Billion Over the Next Decade 2Health News:Increasing Health Center Capacity by 20 Million Patients Could Save More Than $200 Billion Over the Next Decade 3
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 50 OD...
Colloidal Gold Conjugated, Protein A - 50 OD...
Colloidal Gold Conjugated, Protein A - 12 OD...
Medicine Products: